



# Developing EPHT Modules for Neurodegenerative Diseases: Opportunities and Challenges

---

Mark A. Werner, Ph.D.

Wisconsin Division of Public Health



# Presentation Objectives

---

- Describe these conditions and the basis for interest in environmental etiologies
- Characterize the features of WI mortality data for ALS
- Discuss progress to date on establishing EPHT modules for MS and ALS in Wisconsin



## Collaborators

---

- WI DPH: Katrina Boyd, Marni Bekkedal, Kristen Malecki, Henry Anderson;
- UW SMPH: Ben Brooks, Marty Kanarek
- Jeremy Otte, NMSS WI

A teal circular graphic is located in the top-left corner of the slide, partially overlapping the white background.

# Multiple Sclerosis

---

- Autoimmune disease that primarily affects the central nervous system
- Chief feature is loss of myelin leading to sclerosis
- Symptoms stem from impaired neural impulse conduction



# Symptoms of MS

---

- Primary symptoms:
  - Impaired balance, coordination, ability to walk
  - Reduced visual and cognitive function
  - Impaired bowel and bladder control
  - Chronic neck, head and body pain
- Secondary symptoms
  - Headache, hearing loss, tremor, difficulty swallowing.
- Relapse and remission are common

A teal circular graphic is located in the top-left corner of the slide, partially overlapping the edge.

# Amyotrophic Lateral Sclerosis

---

- A progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord
- Degeneration of motor neurons leads to loss of voluntary motor function and virtual paralysis
- Mean survival time: 3-5 years



	MS	ALS
New Annual Diagnoses (US)	10,000	5600
Gender (M/F)	30/70	60/40
Mean Age of Onset	30-35	55



# MS and the Environment

---

- More frequently diagnosed in temperate climates than in subtropical or tropical climates
  - Orkney Islands (Scotland): 250 per 100,000
  - Japan: 2 per 100,000
- People born in high-prevalence areas who move to low-prevalence areas have reduced prevalence (e.g., if before age 15)
- Evidence for genetic and viral etiologies

# ALS and the Environment

---

- Excesses observed among Gulf War veterans
  - Recognized as 'service-related illness' by VA
  - 40 cases among 700,000 veterans
- High rates of ALS-like syndrome linked to cyanobacterial neurotoxin exposure in Guam
- ALS-like syndrome induced in rabbit model upon injection of aluminum



# MS and ALS

## Barriers to Surveillance

---

- Low incidence and prevalence
- Relationship between diagnosis and date of onset is variable
- Differences in diagnostic criteria among physicians
- Lack of well-developed disease registries



# Registries

---

- Used to aggregate case data for disease surveillance and to obtain patients for clinical trials
- Examples:
  - NARCOMS (North American Research Committee On Multiple Sclerosis) Registry
  - VA ALS Registry



## MS, ALS and EPHT

---

- Standardized data collection across states needed to assemble sufficient case numbers for meaningful surveillance
- EPHT networks = platforms to explore relationships between new and emerging registry data and environmental data

# ALS Mortality in WI

---

- Goals:
  - Summarize how ALS deaths were classified and characterize utility of available geographically-specific data
- Review of records from 1989-1998
- Records included with ALS as underlying cause of death (UCOD) or primary cause of death

# ALS Mortality in WI

---

- Total of 1047 deaths recorded for which ALS was UCOD or primary cause of death (ICD-9 = 335.2)
  - UCOD
    - ALS = 508
    - Respiratory Arrest = 229
    - Pneumonia = 65
    - Inhalation of Food or Vomitus = 35
    - Cardiac Arrest = 31

## ALS Mortality in WI

---

Place of Death	Number	Percent
Primary Care Hospital	389	37.2
<i>Nursing Home</i>	<i>280</i>	<i>26.7</i>
Other (private residence, etc.)	378	36.1

A teal circular graphic is located in the top-left corner of the slide, partially overlapping the edge.

## ALS Mortality in WI

---

- Use of administrative mortality data offers some insight into coding and geographical case distribution
- Debilitating nature of condition decreases the ability to use death address as a useful site for assessing pre-diagnosis exposure

# Case Definitions

## Diagnostic Criteria

---

- Until recently, both MS and ALS diagnoses were made on the basis of widely-variable criteria
- El Escorial criteria have emerged for ALS
- MS
  - Three primary criteria:
    - CSF findings
    - MRI
    - Clinical observation

**Do you have weakness of the arms  
or legs for which you consulted a  
neurologist?**

**Yes**

**No**

**A,C**

**Were you  
diagnosed  
with  
multiple  
sclerosis or  
MS?**

**Were you  
diagnosed  
with motor  
neuron  
disease or  
ALS?**

**Yes**

**No**

**Yes**


**No**

**A**

**A,B**


**A,B**

**A,C**




**MacDonald Criteria**  
**Poser Criteria**  
**Schmacher Criteria**

**A2**




**B**



**El Escorial Criteria - 1994**

**B2**



**El Escorial Criteria - 1994**

# Current Approach

- Obtain case information from advocacy group records
  - Develop approach to confirm diagnosis in subset of patient population
- For ALS, consider supplementation with clinic-based case ascertainment outside Milwaukee service area
- Describe risk profile based on statewide environmental hazard data

# Summary

- Administrative data can be informative, but currently-available data are insufficient as a sole basis for useful EPHT network content
- Lack of well-developed disease registries hampers ability to assess surveillance
- National MS/ALS surveillance plan under development

**Do you have any abnormal sensations, e.g. aching, numbness, tingling, burning?**

**Yes**   **No**

**Do you have any abnormal disorder of vision, e.g. double vision, loss of vision in one eye?**

**Yes**   **No**

**Do you have any difficulty controlling your bladder or bowel function?**


**Yes**   **No**

**Do you have any difficulty drinking a glass of water or writing due to a tremor?**


**Yes**   **No**

**Do you have any trouble with speech or swallowing?**

**Yes**   **No**  
**Stop**



**A1**



**MacDonald Criteria**  
**Poser Criteria**  
**Schmacher Criteria**

**A3**

**Was lumbar  
puncture positive  
for elevated  
CSF IgG Index  
or  
immunoglobulin?**

**Yes**

**No**

**Was lumbar  
puncture  
positive for  
elevated CSF  
Oligoclonal  
Bands?**

**Yes**

**No**


**Was lumbar  
puncture  
positive for  
elevated CSF  
Myelin Basic  
Protein?**

**Yes**

**No**

**MacDonald Criteria  
Poser Criteria  
Schumacher Criteria**

**A4**



**A5**

**Did you have a electrical stimulation examination of your arms and/or legs named somatosensory evoked response?**

**Yes**

**No**

**Was it abnormal consistent with MS?**

**Yes**

**No**

**A A1 A2 A4**

**A A1 A2 A4**

**A A1 A2 A4 B**

**MacDonald Criteria**  
**Poser Criteria**  
**Schumacher Criteria**

**B1**

**Did you have increased reflexes  
[hyperreflexia] or increased muscle  
stiffness[spasticity] or a Babinski sign  
[upgoing toe]?**

**Yes**

**No**

**Were any of these signs consistent with  
the diagnosis of motor neuron disease  
or ALS?**

**Yes**

**No**

**Stop**

**Bulbar**

**Arms**

**Legs**

**Yes**

**No**

**Yes**

**No**

**Yes**

**No**

**El Escorial Criteria - 1994**